 |
|
|
| |
Hepatitis B viral control maintained during extended follow up of HBeAg- chronic hepatitis B (CHB) subjects who
discontinued nucleos(t)ide analogue (NA) therapy after completion of AB-729 treatment, and in HBeAg+ subjects
still on NA therapy
|
| |
| |
AASLD 2022 Nov 4-8
MF Yuen1, J Holmes2, S I Strasser3, A Leerapun4, W Sukeepaisarnjaroen5, P Tangkijvanich6, V Sharma7, E Medvedeva7, EP Thi8, G Picchio7, T Eley7, KD Sims7
1Queen Mary Hospital, The University of Hong Kong, Hong Kong, 2St. Vincent's Hospital, Melbourne, Australia, 3Royal Prince Alfred Hospital, Sydney, Australia, 4Chiang Mai University, Chiang Mai, Thailand, 5Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand, 6Chulalongkorn University, Bangkok, Thailand, 7Clinical Development, Arbutus Biopharma, 8Research/Discovery, Arbutus Biopharma
|
| |
|
|
|
|
|
